Literature DB >> 8984703

Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa.

D Schäfer1, U Lindenthal, M Wagner, P L Bölcskei, H W Baenkler.   

Abstract

BACKGROUND: Eicosanoids such as prostaglandin E2 (PGE2), thromboxane A2 (TXA2), and peptidoleukotrienes (pLT) are known to be biologically highly active lipid mediators, especially in human lung epithelium. PGE2 is thought to have mostly bronchoprotective effects, whereas pLT and TXA2 are bronchoconstrictive. This study was undertaken to assess the release and interaction of eicosanoids in human bronchial biopsy specimens of normal and inflamed mucosa.
METHODS: Bronchial biopsy specimens were obtained from 16 patients, seven controls without signs of inflammation and nine patients with severe inflammatory processes in the epithelium. The release of pLT, TXA2 (measured as TXB2), and PGE2 was investigated using a "functional in vitro test" and the addition of several stimuli.
RESULTS: Specimens incubated with arachidonic acid released higher amounts of pLT, TXB2, and PGE2 than unstimulated specimens. Preincubation with PGE2 revealed significant inhibition of arachidonic acid-induced release of pLT and TXB2 (> 50%). The inhibitory effect was higher in normal than in inflamed epithelium.
CONCLUSIONS: Exogenous PGE2 has inhibitory effects on the release of pLT and TXB2 in human bronchial biopsy specimens. This finding could explain the bronchoprotective effect of inhaled PGE2 in normal subjects and asthmatic subjects as direct eicosanoid interactions. It also supports the concept of PGE2 as a bronchoprotective endogenous substance. The complex effects of PGE2 as a modulating mediator in inflammation may be worth investigating.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984703      PMCID: PMC472615          DOI: 10.1136/thx.51.9.919

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  Thromboxane A2: effects on airway and vascular smooth muscle.

Authors:  J Svenssen; K Strandberg; T Tuvemo; M Hamberg
Journal:  Prostaglandins       Date:  1977-09

2.  Prostaglandin E2 and aspirin-induced asthma.

Authors:  A Szczeklik
Journal:  Lancet       Date:  1995-04-22       Impact factor: 79.321

3.  Problems of PGE antisera specificity.

Authors:  F Dray; S Mamas; B Bizzini
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

4.  Inhibition of bronchial hyperresponsiveness to histamine induced by intravenous administration of leukotriene C4 by novel thromboxane A2 receptor antagonists ONO-NT-126 and ONO-8809 in guinea-pigs.

Authors:  M Kurosawa; S Yodonawa; H Tsukagoshi
Journal:  Clin Exp Allergy       Date:  1993-10       Impact factor: 5.018

5.  Bronchoconstrictor effects of leukotriene C in humans.

Authors:  J W Weiss; J M Drazen; N Coles; E R McFadden; P F Weller; E J Corey; R A Lewis; K F Austen
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

6.  Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin.

Authors:  G J Roth; C J Siok
Journal:  J Biol Chem       Date:  1978-06-10       Impact factor: 5.157

7.  Caffeic acid is a selective inhibitor for leukotriene biosynthesis.

Authors:  Y Koshihara; T Neichi; S Murota; A Lao; Y Fujimoto; T Tatsuno
Journal:  Biochim Biophys Acta       Date:  1984-01-17

8.  Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.

Authors:  Z Marom; J H Shelhamer; M K Bach; D R Morton; M Kaliner
Journal:  Am Rev Respir Dis       Date:  1982-09

9.  Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils.

Authors:  E A Ham; D D Soderman; M E Zanetti; H W Dougherty; E McCauley; F A Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

View more
  8 in total

Review 1.  [Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease].

Authors:  C Umbreit; J C Virchow; C Thorn; K Hörmann; L Klimek; O Pfaar
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

2.  A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma.

Authors:  W Wasiak; M Szmidt
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

3.  Strategy for NSAID administration to aspirin-intolerant asthmatics in combination with PGE2 analogue: a theoretical approach.

Authors:  A Dobovišek; A Fajmut; M Brumen
Journal:  Med Biol Eng Comput       Date:  2011-11-26       Impact factor: 2.602

4.  Salicylate intolerance: pathophysiology, clinical spectrum, diagnosis and treatment.

Authors:  Hanns-Wolf Baenkler
Journal:  Dtsch Arztebl Int       Date:  2008-02-22       Impact factor: 5.594

5.  Pathogenic Mechanisms and In Vitro Diagnosis of AERD.

Authors:  Dirk Schäfer; Steffen Maune
Journal:  J Allergy (Cairo)       Date:  2012-05-10

6.  Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation.

Authors:  Neil Martin; Andrew Ruddick; Greer K Arthur; Heidi Wan; Lucy Woodman; Christopher E Brightling; Don J L Jones; Ian D Pavord; Peter Bradding
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

7.  Prostaglandin D2-supplemented "functional eicosanoid testing and typing" assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study.

Authors:  Dirk Schäfer; Peter Dreßen; Stefan Brettner; Norbert-Folke Rath; Gerhard J Molderings; Katrin Jensen; Christina Ziemann
Journal:  J Transl Med       Date:  2014-08-12       Impact factor: 5.531

8.  Dynamic model of eicosanoid production with special reference to non-steroidal anti-inflammatory drug-triggered hypersensitivity.

Authors:  Aleš Fajmut; Tadej Emeršič; Andrej Dobovišek; Nataša Antić; Dirk Schäfer; Milan Brumen
Journal:  IET Syst Biol       Date:  2015-10       Impact factor: 1.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.